Bioventures 2018 L.P. Mpm Sells 38,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 38,500 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $7.11, for a total transaction of $273,735.00. Following the sale, the insider directly owned 4,106,452 shares in the company, valued at $29,196,873.72. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 9th, Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81.
• On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $6.42 on Friday. The stock’s fifty day moving average is $7.02 and its 200-day moving average is $9.06. The stock has a market capitalization of $249.99 million, a PE ratio of -1.62 and a beta of -0.25. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. As a group, analysts forecast that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP boosted its stake in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $19,013,000. 5AM Venture Management LLC bought a new stake in shares of Entrada Therapeutics during the second quarter worth approximately $29,854,949. GSA Capital Partners LLP bought a new stake in shares of Entrada Therapeutics during the second quarter worth approximately $648,000. Finally, Nantahala Capital Management LLC acquired a new position in Entrada Therapeutics in the second quarter valued at approximately $2,212,232. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on TRDA. Guggenheim dropped their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Roth Capital reissued a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 5th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Entrada Therapeutics News Summary

Here are the key news stories impacting Entrada Therapeutics this week:

• Neutral Sentiment: Entrada announced two recipients of its 2026 DREAMS Grant Program, awarding $50,000 each to projects addressing healthcare disparities and improving outreach to underserved members of the global Duchenne muscular dystrophy community. The initiative supports the company’s patient-focused reputation, although the grants are not expected to have a significant direct financial impact. Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
• Neutral Sentiment: A report showing short interest of zero shares and a zero-day days-to-cover ratio appears internally inconsistent, including a reported “NaN” percentage change. As a result, it provides no meaningful indication of short-selling pressure or potential for a short squeeze.
• Negative Sentiment: Major shareholder Bioventures 2018 L.P. MPM disclosed additional sales of TRDA shares, including 28,837 shares on September 9 for approximately $206,000 and 192,500 shares on September 8 for about $1.43 million. The shareholder also sold shares in earlier September transactions, bringing the reported series to more than 433,000 shares. Although the fund still owns a substantial stake, repeated insider disposals can weigh on investor confidence and increase perceived supply. Entrada Therapeutics Major Shareholder Share Sale

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.